Findings confirmed the approved 600mg IV dose was optimal for slowing disability progression in relapsing MS. A phase 3 study evaluating a higher dose of ocrelizumab in adults with relapsing multiple ...

The National Institute for Health and Care Excellence (NICE) has recommended ublituximab (Briumvi) for treating people with relapsing remitting multiple sclerosis (MS). The drug should be available ...

Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 monthsTop-line data expected year-end ...

Please provide your email address to receive an email when new articles are posted on . Adults either continued to receive ublituximab or switched from teriflunomide to ublituximab in this 3-year open ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for tolebrutinib for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS).

NEW YORK, Jan. 26, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX) today announced the commercial launch of BRIUMVI™ (ublituximab-xiiy), for the treatment of relapsing forms of multiple ...

--TG Therapeutics, Inc., today announced updated data presentations including new six-year data from the ULTIMATE I& II Phase 3 trials evaluating BRIUMVI ® in patients with relapsing forms of multiple ...

Please provide your email address to receive an email when new articles are posted on . The most common comorbidity for both subsets of the study population was obesity. Risk for infection-related ...

- Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatment - - Phase III studies for fenebrutinib in ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...